← Kailera Therapeutics, Inc. (KLRA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Kailera Therapeutics, Inc. (KLRA)
Pharmaceutical Preparations · market cap $1.7B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Kailera Therapeutics (KLRA) is a clinical-stage pharmaceutical company with 145 employees and a ~$2.6B market cap, focused on obesity and metabolic disease. Its lead asset KAI-9531 is in Phase 3 for Obesity With Diabetes, while it also runs a Phase 3 program with Semaglutide for Obesity and a Phase 2 program for KAI-7535 in Obesity. The company carries ~$111.8M in cash, representing roughly 4.9 months of runway — a near-term financing constraint that is central to the investment case.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-05-15 (est.)Phase 2 · Ribupatideimp 7/10
- 2027-07-07 (est.)Phase 2 · KAI-7535imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ribupatide | Phase 3 | Obesity |
| KAI-7535 | Phase 2 | Obesity |
| KAI-9531 | Phase 3 | Obesity With Diabetes |
Price & technical context
3-month
-49.8%
6-month
—
12-month
—
52-wk range
$10.99–$26.00
vs 50-day MA
-30.3%
vs 200-day MA
—
Realized vol
68.4%
Max drawdown
-57.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KLRA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.